International Edition
Latest News
Technology

Defective Antibodies Cost US $1 Billion Yearly; Open Platform Shares Validation Data

Defective research antibodies cost United States scientists roughly $1 billion every year and undermine medical studies. Laboratories rely on these biochemical tools to target and measure specific proteins inside living organisms. Poorly performing reagents compromise experiments on cancer…

Defective Antibodies Cost US

Defective research antibodies cost United States scientists roughly $1 billion every year and undermine medical studies.

Laboratories rely on these biochemical tools to target and measure specific proteins inside living organisms. Poorly performing reagents compromise experiments on cancer and other conditions, creating false results and destroying precious patient samples.

A single flawed pancreatic cancer study wasted two years of laboratory work.

Ethical concerns also mount when experiments fail. Animals are euthanized to produce antibodies, and human donors provide irreplaceable tissue samples. When laboratories select unreliable reagents, those sacrifices yield no medical progress.

High costs and pressure to publish discourage many teams from validating commercial reagents. Researchers tested commercially available antibodies targeting the C9ORF72 protein linked to amyotrophic lateral sclerosis, or ALS, in 2019. The test revealed that 61% of those products failed to detect the target protein.

Investigators created the ALS Reproducible Antibody Platform to publish open-source data on validated reagents. The platform characterizes 303 antibodies against 33 proteins using Western blot, immunoprecipitation, and immunofluorescence testing.

Public-private partnerships funded the initiative through the ALS Association in the United States, the Motor Neurone Disease Association in the United Kingdom, and the ALS Society of Canada.

The Tanenbaum Open Science Institute provided crucial support by establishing open-science guidelines that prohibit patents or intellectual property restrictions on the data.

“Our réactifs et méthodes sont disponibles ouvertement afin que d’autres chercheurs puissent reproduire ces tests et mener leurs propres expériences,” said Peter McPherson, James McGill Professor of neurology, neurosurgery, anatomy, and cell biology at McGill University, and scientific director of the Structural Genomics Consortium at The Neuro.

* What causes research antibodies to fail? Producing effective antibodies is technically difficult and expensive, and many laboratories lack the time or resources to validate commercial products before use.
* How does the ALS Reproducible Antibody Platform share data? The platform releases all validation data openly without patents or subscription paywalls, allowing global researchers to access Western blot and immunofluorescence results.
* Which organizations fund the platform? The initiative unites the ALS Association, the Motor Neurone Disease Association, and the ALS Society of Canada alongside support from the Tanenbaum Open Science Institute, according to Mcgill.

Peter McPherson built his expertise in protein function through a doctorate in neuroscience at the University of Iowa, followed by post-doctoral training at Yale.

His laboratory at McGill University currently investigates the biological basis of neurodegenerative conditions by examining how membrane trafficking defects contribute to diseases such as Huntington’s, Parkinson’s, and ALS. His research has notably demonstrated that certain proteins, including the ALS-linked C9orf72, contain DENN domains that function enzymatically to regulate cellular pathways.

About the author: Technology Desk

Technology Desk at Archynewsy.